A new push to loosen federal restrictions on peptides could fuel a boom similar to weight-loss drugs — even as research and clinical trials lag.
Go deeper:
Washington is finally confronting rising health care costs — but taking on powerful industry players comes with tradeoffs that could stall reform.
Go deeper: